#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thalassaemia Vascular malformation Spinal cord injury cervical Atypical haemolytic uraemic syndrome Orthostatic hypotension Leukocyte adhesion deficiency Follicular lymphoma stage II Short-bowel syndrome Prolymphocytic leukaemia Chronic inflammatory demyelinating polyradiculoneuropathy Hereditary optic atrophy Hairy cell leukaemia recurrent Acquired C1 inhibitor deficiency Usher's syndrome NTRK gene fusion overexpression More trials…

    Learn about Rare Diseases

    Atypical haemolytic uraemic syndrome – Diagnostics Shprintzen-Goldberg syndrome – Trials in Disease Phenylketonuria Marginal zone lymphoma – Treatment Inclusion body myositis – Trials in Disease Piriformis syndrome – Diagnostics Osteosarcoma – Treatment Combined immunodeficiency – Life with Disease Testicular leiomyosarcoma Marginal zone lymphoma refractory – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Bromhexine Hydrochloride SOFOSBUVIR L-Histidine Gsk4532990A USNOFLAST Acoramidis Hydrochloride AZD5335 Cefalexin Macitentan Gd2Il18Cart Daxdilimab Florbetaben (18F) Gsk6097608 Mrna-3210 Lsta1 Remdesivir Magnesium Chloride ALKYLATING AGENTS Trometamol Reparixin More therapies…

    Learn about Your Condition

    EGFR gene mutation Dizziness Bronchiectasis Abdominal infection Yellow fever Plasma cell myeloma Retinoblastoma Breast cancer metastatic Labour induction Endometrial cancer stage IV Vascular dementia Lymphoedema Brain stem glioma Ovarian cancer Conjunctivitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Early Detection of Triple-Negative Breast Cancer Relapse Using 68Ga-FAPI-46 for Patients at High Risk

    Recruiting

    2 1 1
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    France

  • Study on Olaparib for Patients with p53abn Endometrial Cancer After Chemoradiation Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Olaparib
    France

  • Study on Maintenance Therapy with Cisplatin, Durvalumab, and Trastuzumab for Patients with Advanced Biliary Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Binimetinib
    • Cisplatin
    • Durvalumab
    Belgium France

  • Continued Cancer Treatment Study with Abiraterone, Ipatasertib, Tiragolumab, and Drug Combination for Patients from Previous Genentech/Roche Trials

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Abiraterone
    • Divarasib
    • Entrectinib
    Belgium France Greece Poland

  • Study on Durvalumab for Patients with High-Risk Endometrial Cancer After Surgery

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Endometrial cancer
    Investigated Drugs:
    • Durvalumab
    Belgium Czechia France Germany Italy The Netherlands

  • Study of Tucatinib, Etoposide, and Trastuzumab for Patients with Metastatic HER2+ Breast Cancer After Progression or Capecitabine Toxicity

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Etoposide
    • Trastuzumab
    • Tucatinib
    France

  • Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Anastrozole
    • Camizestrant
    • Exemestane
    Austria Belgium Bulgaria Czechia France Germany +8

  • Study on the Safety and Effectiveness of VB10.16 and Pembrolizumab for Patients with HPV16-Positive Head and Neck Cancer

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • Vb10.16
    • Pembrolizumab
    Czechia France Germany Hungary Norway Poland +1

  • Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    • Lutetium (177Lu) Edotreotide
    Belgium France Italy Spain

  • Study on ONC201 and Everolimus with Radiotherapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Other Diffuse Midline Gliomas in Children, Adolescents, and Adults

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Brain stem glioma
    Investigated Drugs:
    • 2,4,6,7,8,9-Hexahydro-4-((2-Methylphenyl)Methyl)-7-(Phenylmethyl)Imidazo(1,2-A)Pyrido(3,4-E)Pyrimidin-5(1H)-One
    • Everolimus
    Austria Belgium Czechia Denmark Finland France +5
Previous Page
1 … 7 8 9 10 11 … 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!